Yuyu Pharma, Inc. (KRX:000220)

Yuyu Pharma Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	28,669	41,832	30,605	25,839	50,263	20,323
Trading Asset Securities	-	817.27	1,749	4,939	-	180
Cash & Short-Term Investments	28,669	42,650	32,354	30,778	50,263	20,503
Cash Growth	-34.67%	31.82%	5.12%	-38.77%	145.15%	-23.63%
Accounts Receivable	20,826	17,662	20,801	21,940	19,528	17,782
Other Receivables	1,035	2,069	3,653	2,876	3,265	2,125
Receivables	21,861	19,731	24,455	24,816	22,793	19,908
Inventory	44,317	38,628	44,152	39,832	25,225	23,689
Prepaid Expenses	265.02	327.71	341.03	238.84	115.08	97.7
Other Current Assets	1,553	611.32	294.62	692.94	491.06	269.6
Total Current Assets	96,665	101,947	101,597	96,358	98,888	64,467
Property, Plant & Equipment	89,734	89,987	81,403	81,371	80,341	78,073
Long-Term Investments	10,001	8,626	6,867	5,944	5,712	5,077
Goodwill	153.77	153.77	503.22	50.83	50.83	50.83
Other Intangible Assets	2,810	2,977	3,764	3,666	4,087	3,786
Long-Term Accounts Receivable	-	-	-0	493.76	345.28	632.98
Long-Term Deferred Tax Assets	991.35	909.48	-	-	-	-
Other Long-Term Assets	1,963	2,988	4,079	6,826	3,561	2,814
Total Assets	202,418	207,687	198,214	195,205	192,985	154,901
Accounts Payable	9,976	9,475	10,952	15,841	8,982	5,287
Accrued Expenses	1,390	1,494	1,504	1,613	1,553	1,312
Short-Term Debt	26,568	31,186	24,482	36,164	8,200	3,500
Current Portion of Long-Term Debt	1,610	1,475	448.73	718.28	1,812	888.5
Current Portion of Leases	499.13	581.1	455.55	542.86	414.94	589.67
Current Income Taxes Payable	826.7	1,043	574.8	297.04	219.32	-
Other Current Liabilities	13,888	19,226	11,558	9,140	8,832	6,821
Total Current Liabilities	54,758	64,480	49,975	64,316	30,015	18,399
Long-Term Debt	33.32	33.32	13,640	1,600	28,456	14,592
Long-Term Leases	244.09	369.17	380.92	250.96	282.81	379.95
Pension & Post-Retirement Benefits	3,223	2,859	2,286	1,732	2,491	2,473
Long-Term Deferred Tax Liabilities	4,288	4,094	4,360	3,690	2,897	1,809
Other Long-Term Liabilities	774.33	788.34	7,215	242.12	158.07	212.16
Total Liabilities	63,320	72,624	77,858	71,831	64,300	37,865
Common Stock	17,609	17,609	17,609	17,609	17,609	8,412
Additional Paid-In Capital	64,981	64,973	65,075	58,803	58,803	53,467
Retained Earnings	30,560	25,789	20,171	31,396	36,540	41,914
Treasury Stock	-7,788	-5,791	-5,791	-6,156	-4,371	-4,371
Comprehensive Income & Other	20,170	20,059	12,531	12,572	13,107	13,639
Total Common Equity	125,532	122,639	109,595	114,224	121,689	113,062
Minority Interest	10,973	9,831	8,168	6,558	4,404	2,677
Shareholders' Equity	139,097	135,063	120,356	123,374	128,685	117,036
Total Liabilities & Equity	202,418	207,687	198,214	195,205	192,985	154,901
Total Debt	28,955	33,644	39,407	39,276	39,166	19,950
Net Cash (Debt)	-286.01	9,005	-7,053	-8,499	11,097	552.89
Net Cash Growth	-	-	-	-	1907.08%	-
Net Cash Per Share	-16.18	535.91	-433.55	-512.57	695.34	46.01
Filing Date Shares Outstanding	17.07	16.18	16.18	16.35	16.66	14.92
Total Common Shares Outstanding	17.07	16.18	16.18	16.35	16.66	14.92
Working Capital	41,907	37,468	51,621	32,042	68,873	46,068
Book Value Per Share	7355.34	7578.44	6772.38	6985.77	7306.09	7579.20
Tangible Book Value	122,568	119,509	105,327	110,506	117,551	109,226
Tangible Book Value Per Share	7181.71	7384.99	6508.66	6758.42	7057.65	7322.03
Land	39,962	39,962	30,380	30,380	30,380	30,380
Buildings	54,314	53,192	53,397	52,138	48,966	48,912
Machinery	42,916	42,217	39,229	37,067	33,334	30,809
Construction In Progress	685.29	385.8	259.36	1,333	3,454	202.8

Source: S&P Global Market Intelligence. Standard template. Financial Sources.